Search results
Genentech, Inc. historic stock prices and company profile. Historically stock information and prices for 321:843475 company.
Genentech started shipping product on June 30, 2006, the day the product was approved. 2010: Actemra (tocilizumab): The first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat rheumatoid arthritis.
Genentech, Inc. (DNA.NYSE): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Genentech, Inc. | Nyse: DNA | Nyse.
Genentech, Inc. became a pioneer of biotechnology when it was founded in the late 1970s. A publicly traded company, Genentech is controlled by Roche Holding Ltd. (parent of Swiss pharmaceutical giant Hoffmann-La Roche) through that company's 66 percent stake, but is allowed to operate independently.
2 wrz 2002 · +951% of historical performance More than 20 years at your side + 10,00,000 members
Genentech, Inc.: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | Nyse: DNA | Nyse.
The South San Francisco–based biotech giant has earned a place on Fortune’s Best Companies list for 24 consecutive years. At a time when employee wellness is front and center, Genentech’s ...
